Analyst consensus rating
Aktis Oncology Analyst Rating: Strong Buy
Direct answer
Aktis Oncology's consensus rating is Strong Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $35.88.
Forecast evidence checked November 17, 2026.
Get free Aktis Oncology email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $16.16
- Average price target
- $35.88
- High price target
- $40.00
- Low price target
- $33.00
- Low target gap
- +104.2%
- Target upside
- +122%
- High target gap
- +147.5%
- Target range width
- 43.3%
- Consensus rating
- Strong Buy
- Analysts
- 8
- Evidence date
- November 17, 2026
- Valid through
- November 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Aktis Oncology?
Aktis Oncology has a verified Strong Buy consensus. The same dataset has an average price target of $35.88.
How far are Aktis Oncology's low and high targets from the recorded price?
The low target implies +104.2%, while the high target implies +147.5%.
How many analysts are included in Aktis Oncology's consensus?
The verified consensus includes 8 analysts.
How is Aktis Oncology's target upside or downside calculated?
The average target of $35.88 is divided by the recorded price of $16.16, then one is subtracted to produce +122%. This does not guarantee a future return.
When was Aktis Oncology's analyst forecast verified?
The data was verified on 2026-11-17. The dataset is valid through 2026-11-24.